GRT-R910 / Gritstone bio, The University of Manchester - LARVOL DELTA

Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults (clinicaltrials.gov) - P1 | N=81 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8 • IL10 • TNFA

Preliminary results of durable immune response induced by a self-amplifying mRNA (samRNA) SARS-CoV-2 vaccine candidate, GRT-R910, in adults previously vaccinated with mRNA or AZD1222 primary series (IDWeek 2023) - No abstract available

Clinical • Infectious Disease • Novel Coronavirus Disease

An Interim Report of the Safety, Reactogenicity, and Immunogenicity of a Self-amplifying mRNA (samRNA) COVID-19 Vaccine GRT-R910 as a Booster in Healthy Adults (IDWeek 2023) - No abstract available

Clinical • Infectious Disease • Novel Coronavirus Disease

GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults. (PubMed, Nat Commun) - P1 | "GRT-R910 increased and/or broadened functional Spike-specific T cell responses and primed functional T cell responses to conserved non-Spike epitopes. This study is limited due to small sample size, and additional data from ongoing studies will be required to corroborate these interim findings."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Gritstone bio, Inc. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Gritstone bio, Inc. | Trial completion date: Jan 2024 ➔ May 2023 | Trial primary completion date: Jan 2024 ➔ May 2023

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

First study of a self-amplifying mRNA (samRNA) vaccine, GRT-R910, as a COVID-19 boost in healthy volunteers ≥60 years of age: preliminary evidence of sustained immunogenicity (ECCMID 2023) - No abstract available

Clinical • Infectious Disease • Novel Coronavirus Disease

Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Gritstone bio, Inc. | Recruiting ➔ Active, not recruiting | N=120 ➔ 40

Enrollment change • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults (clinicaltrials.gov) - P1 | N=81 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting ➔ Active, not recruiting | N=135 ➔ 81

Enrollment change • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8 • IL10 • TNFA

Title: A novel low-dose self-amplifying mRNA vaccine (GRT-R910) induces strong and broad boost in cellular and humoral immune response following primary series with a chimpanzee adenovirus SARS-CoV-2 vaccination (IDWeek 2022) - No abstract available

Preclinical • Infectious Disease • Novel Coronavirus Disease

Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults (clinicaltrials.gov) - P1 | N=135 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Sep 2022 ➔ Oct 2023 | Trial primary completion date: Sep 2022 ➔ Oct 2023

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8 • IL10 • TNFA

Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Gritstone bio, Inc. | N=20 ➔ 120 | Trial completion date: Jan 2023 ➔ Jan 2024 | Trial primary completion date: Jan 2023 ➔ Jan 2024

Enrollment change • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: Gritstone Bio, Inc.; N=120 ➔ 20

Clinical • Enrollment change • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

Study of GRT-R910 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Boost Vaccine in Healthy Volunteers (clinicaltrials.gov) - P1; N=120; Recruiting; Sponsor: Gritstone Oncology, Inc.

Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG